MX394356B - Métodos y composiciones para tratar hiperhidrosis. - Google Patents

Métodos y composiciones para tratar hiperhidrosis.

Info

Publication number
MX394356B
MX394356B MX2018008694A MX2018008694A MX394356B MX 394356 B MX394356 B MX 394356B MX 2018008694 A MX2018008694 A MX 2018008694A MX 2018008694 A MX2018008694 A MX 2018008694A MX 394356 B MX394356 B MX 394356B
Authority
MX
Mexico
Prior art keywords
muscarinic antagonist
methods
compositions
subject
hyperhidrosis
Prior art date
Application number
MX2018008694A
Other languages
English (en)
Spanish (es)
Other versions
MX2018008694A (es
Inventor
Iii Benjamin F Mcgraw
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of MX2018008694A publication Critical patent/MX2018008694A/es
Publication of MX394356B publication Critical patent/MX394356B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
MX2018008694A 2016-01-20 2016-01-20 Métodos y composiciones para tratar hiperhidrosis. MX394356B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/014150 WO2017127073A1 (en) 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis

Publications (2)

Publication Number Publication Date
MX2018008694A MX2018008694A (es) 2019-05-15
MX394356B true MX394356B (es) 2025-03-24

Family

ID=59314209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008694A MX394356B (es) 2016-01-20 2016-01-20 Métodos y composiciones para tratar hiperhidrosis.

Country Status (15)

Country Link
US (4) US10328057B2 (enExample)
EP (1) EP3405191B1 (enExample)
JP (1) JP6841834B2 (enExample)
KR (2) KR102495757B1 (enExample)
CN (1) CN108697688A (enExample)
AU (2) AU2016388308B2 (enExample)
BR (1) BR112018014661A2 (enExample)
CA (1) CA3011683C (enExample)
DK (1) DK3405191T3 (enExample)
HK (1) HK1258825A1 (enExample)
MX (1) MX394356B (enExample)
RU (1) RU2718906C2 (enExample)
TW (2) TWI810150B (enExample)
WO (1) WO2017127073A1 (enExample)
ZA (1) ZA201805490B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
JP6841834B2 (ja) 2016-01-20 2021-03-10 テラヴィダ, インコーポレイテッドTheraVida, Inc. 多汗症の処置のための方法および組成物
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
KR20220027943A (ko) 2019-07-05 2022-03-08 스웨디쉬 매치 노스 유럽 에이비 니코틴 함유 입자를 포함하는 충전 재료를 포함하는 경구 파우치형 니코틴 제품
EP4356759A3 (en) 2019-11-20 2024-07-03 Swedish Match North Europe AB An oral pouched nicotine product including a filling material comprising nicotine particles
EP3967311A1 (en) * 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
PL4018849T3 (pl) 2020-12-22 2025-02-10 Swedish Match North Europe Ab Wyrób w saszetkach do użytku doustnego
EP4018847B1 (en) 2020-12-22 2024-09-18 Swedish Match North Europe AB A pouched product for oral use
EP4018848B1 (en) 2020-12-22 2024-09-18 Swedish Match North Europe AB A pouched product for oral use comprising a liquid permeable cover material and a filling material
AU2022326451A1 (en) * 2021-08-11 2024-02-08 Theravida, Inc. Pharmaceutical compositions and methods for treating hyperhidrosis
WO2024162929A1 (en) * 2023-01-27 2024-08-08 Ardi Farma Ilac Pazarlama Ticaret Limited Sirketi A controlled release formulation of propiverine

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209505A (en) 1979-04-03 1980-06-24 Mikhail Adib R Pilocarpine mouthwash for dry mouth relief
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
WO1995022962A1 (en) 1994-02-23 1995-08-31 Bm Research A/S Controlled release composition
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1998030208A1 (en) 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
AU734248B2 (en) * 1997-03-26 2001-06-07 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer
SI1041987T1 (sl) 1997-12-22 2006-10-31 Euro Celtique Sa Farmacevtska oralna dozirna oblika, ki obsega kombinacijo opioidnega agonista in naltreksona
AU755790B2 (en) 1997-12-22 2002-12-19 Euro-Celtique S.A. A method of preventing abuse of opioid dosage forms
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
WO2000024423A1 (en) 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
JP2003509439A (ja) 1999-09-14 2003-03-11 スミスクライン・ビーチャム・コーポレイション 水性コーティングされたビーズレットの製法
AU784104B2 (en) 1999-11-11 2006-02-02 Pfizer Health Ab Pharmaceutical formulation containing tolterodine and its use
WO2001054728A1 (fr) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP2005521706A (ja) 2002-03-29 2005-07-21 アルザ・コーポレーシヨン 体積効果的放出制御製剤
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1635795A1 (en) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
EP1651192A1 (en) 2003-08-06 2006-05-03 Nirmal Mulye Pharmaceutical composition containing water soluble drug
DE602004030931D1 (enExample) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
RU2382637C2 (ru) 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
WO2005115340A1 (en) 2004-05-19 2005-12-08 Glatt Air Techniques, Inc. Micropellet containing pellets and method of preparing such pellets
WO2005123042A1 (en) 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
JP2008516893A (ja) 2004-08-27 2008-05-22 スフェリックス,インク. 多層錠剤および生体接着性剤形
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β3作動薬を含有する新規な医薬
CN101287462A (zh) 2005-09-02 2008-10-15 塞拉维达公司 治疗疾病的疗法
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
EP1951186A4 (en) * 2005-10-19 2009-11-04 Menni Menashe Zinger METHODS FOR TREATING HYPERHIDROSIS
CA2680680A1 (en) 2007-03-29 2009-02-19 Panacea Biotec Limited Modified dosage forms of tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
US20090017111A1 (en) 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US9561015B2 (en) * 2007-08-24 2017-02-07 General Electric Company Method and apparatus for voice recording with ultrasound imaging
BRPI0817275A2 (pt) 2007-09-28 2015-06-16 Novartis Ag Combinação farmacêutica de alisquireno e valsartana
JP2011502140A (ja) 2007-10-29 2011-01-20 ルピン・リミテッド トルテロジンの制御放出型医薬組成物
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090247628A1 (en) * 2008-03-25 2009-10-01 Auspex Pharmaceuticals, Inc. Substituted phenylcyclohexylglycolates
SG174658A1 (en) * 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011123815A1 (en) 2010-04-01 2011-10-06 Theravida, Inc. Methods of improving quality of sleep
US20120289560A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
SG194809A1 (en) 2011-05-10 2013-12-30 Theravida Inc Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
US20140105976A1 (en) 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
JP6841834B2 (ja) 2016-01-20 2021-03-10 テラヴィダ, インコーポレイテッドTheraVida, Inc. 多汗症の処置のための方法および組成物

Also Published As

Publication number Publication date
US10610519B2 (en) 2020-04-07
KR102600541B1 (ko) 2023-11-08
DK3405191T3 (da) 2025-05-19
JP6841834B2 (ja) 2021-03-10
AU2016388308A1 (en) 2018-08-02
KR20180102649A (ko) 2018-09-17
TWI810150B (zh) 2023-08-01
CN108697688A (zh) 2018-10-23
MX2018008694A (es) 2019-05-15
US20190307727A1 (en) 2019-10-10
US11779569B2 (en) 2023-10-10
US11185533B2 (en) 2021-11-30
BR112018014661A2 (pt) 2018-12-11
AU2022206709A1 (en) 2022-08-11
US20220047558A1 (en) 2022-02-17
US20170202778A1 (en) 2017-07-20
US10328057B2 (en) 2019-06-25
CA3011683A1 (en) 2017-07-27
KR20230021184A (ko) 2023-02-13
EP3405191B1 (en) 2025-02-19
WO2017127073A1 (en) 2017-07-27
HK1258825A1 (zh) 2019-11-22
US20200188360A1 (en) 2020-06-18
TW202341976A (zh) 2023-11-01
JP2019506401A (ja) 2019-03-07
RU2718906C2 (ru) 2020-04-15
EP3405191A1 (en) 2018-11-28
AU2016388308B2 (en) 2022-08-04
ZA201805490B (en) 2019-11-27
RU2018128047A (ru) 2020-02-20
EP3405191A4 (en) 2019-09-04
CA3011683C (en) 2023-09-26
RU2018128047A3 (enExample) 2020-02-20
KR102495757B1 (ko) 2023-02-06
TW201737906A (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
MX394356B (es) Métodos y composiciones para tratar hiperhidrosis.
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
PE20120713A1 (es) Composiciones sublinguales de dexmedetomidina y metodos para su uso
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
ECSP11011479A (es) Compuestos heterocíclicos de fenoximetilo
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.